Key Highlights

  • Risto-cel met the primary endpoint in the pivotal sickle cell study, Beam Therapeutics (NASDAQ:BEAM) said on November 10, 2026, and a filing could come as early as year-end.
  • Veradermics posted a 36.4 hair count gain at six months in a Phase 3 study of its oral hair-loss pill and has USD 798.4 million of cash.
  • A 56% complete response rate in bladder cancer led enGene to plan a filing by year-end, and PepGen almost doubled on 46.5% splicing correction.
  • A second Phase 3 trial in bipolar mania met its goals for Caplyta, Johnson & Johnson said, setting up a US submission.

1. Beam Therapeutics (NASDAQ:BEAM)

On November 10, Beam Therapeutics (NASDAQ:BEAM) announced that risto-cel achieved the primary efficacy endpoint in the pivotal portion of its BEACON study in severe sickle cell disease, defined as independently adjudicated freedom from severe vaso-occlusive crises for at least 12 consecutive months. Treatment covered 49 patients, 10 of them adolescents, and 31 had finished the required follow-up. At the interim analysis, every secondary endpoint and every primary safety endpoint was met. Beam withheld the share of patients reaching the endpoint and is holding that detail for the American Society of Hematology meeting in December. One patient died in 2024 of respiratory failure, which was judged unrelated to risto-cel and most likely connected to the busulfan conditioning that all such therapies require. A Biologics License Application is planned as early as year-end 2026, potentially the first filing for a base-editing therapy, a technology that alters single DNA letters without cutting both strands. Because two gene therapies for sickle cell are already approved, Beam has to compete on consistency and depth of response. The study is single-arm and open-label, and existing treatments have been adopted slowly given chemotherapy conditioning, long hospital stays and complicated payer negotiations.

2. Veradermics (NYSE:MANE)

VDPHL01, an extended-release oral minoxidil for pattern hair loss, is the product under development at Veradermics (NYSE:MANE). In men, Phase 3 Study 304 met every primary and secondary endpoint, with hair count rising 36.4 hairs per square centimetre at six months on twice-daily dosing and 28.6 on once-daily dosing. The 12-month continuation of Study 302 showed gains of 43.9 on twice-daily dosing, with 89.1% of those patients visibly improved, which suggests results build instead of levelling off. Treatment-related serious adverse events were absent, an important point because systemic minoxidil can affect blood pressure and heart rate. For a single-asset company, the Balance Sheet is unusually strong. Cash and securities of USD 798.4 million at the end of September fund operations into 2030 and cover a filing and early launch with no obvious need to raise equity. The third-quarter net loss was USD 21.0 million. Commercial success looks harder than regulatory success: hair loss is largely a self-pay market, and cheap off-label or compounded low-dose minoxidil is the main rival, so the company must prove its formulation merits a branded price. A study in women is due in the first half of 2027 and could widen the label.

3. enGene (NASDAQ:ENGN)

By year-end, enGene (NASDAQ:ENGN) will start a Biologics License Application for detalimogene, the company said on November 11, following new data from pivotal Cohort 1 of its LEGEND trial in BCG-unresponsive non-muscle invasive bladder cancer. Of 120 evaluable patients, 56% reached a complete response at any time, up from 54%, and the 12-month landmark complete response rate improved to 24% from 13%. Median duration of response grew to 10.1 months, 97% of patients stayed free of progression to muscle-invasive disease, and 86% avoided bladder removal. Safety was mild, with Grade 3 treatment-related events in 4% of patients and no Grade 4 or 5 events. Detalimogene is a non-viral gene therapy placed in the bladder, easier to manufacture than viral Options and well suited to community urology offices. A rolling submission should be complete in the first half of 2027, with potential approval in 2027. Durability is the central question: a 24% response at 12 months sits well below the 56% any-time rate, and competitors in a crowded field have shown higher sustained responses. The trial is single-arm, and a clinical-stage company like enGene will need funding to build a commercial team.

4. PepGen (NASDAQ:PEPG)

On November 10, PepGen (NASDAQ:PEPG) ended up 92.89% at about USD 4.61 after trading more than 120% higher early on. Its FREEDOM2-DM1 Phase 2 trial targets myotonic dystrophy type 1, a disease with no approved disease-modifying therapy. Four monthly doses of PGN-EDODM1 at 10 mg/kg produced mean splicing correction of 46.5% against 6.8% on placebo, which the company described as the highest seen in a multiple-dose study of the disease. Five of six treated patients passed 20% correction, and functional measures including hand opening time and grip strength trended the right way, with no serious adverse events. The numbers are striking, yet this is the longest road to approval of the five. Just six patients received the drug at this dose, so the functional findings are early signals. Before PepGen can hold an end of Phase 2 meeting, planned for the second half of 2027, a partial clinical hold placed in the United States in March 2026 must be lifted, and a competitor's registrational data are due in early 2027. After the close the company proposed a USD 125 million offering, adding to a runway that already extended into 2028, and the shares still gained about 14% on November 11.

5. Johnson & Johnson (NYSE:JNJ)

Caplyta met its primary and key secondary endpoints in Study 452, a second Phase 3 trial in adults with manic episodes of bipolar I disorder, Johnson & Johnson (NYSE:JNJ) said on November 10. At week three, the once-daily 42 mg dose improved the Young Mania Rating Scale score by 3.7 points over placebo, with benefit starting on day three, and clinical response reached 43.9% against 23.7% on placebo. Dizziness, dry mouth and sedation matched the known profile of the drug. Since Study 451 was already positive, the company holds the two pivotal trials usually required for a new indication and plans a US submission, with a decision most likely in 2027. Caplyta came with the 2025 Acquisition of Intra-Cellular Therapies and is approved for bipolar depression, major depressive disorder and schizophrenia, so regulators know the drug well. A mania indication would cover both poles of bipolar I disorder, and low rates of weight gain and movement side effects favour long-term use. Against group sales the commercial uplift is modest, and acute mania is crowded with generic antipsychotics, so pricing and payer access will shape revenue. The Regulatory Risk is nonetheless the lowest of the five.

Where Things Stand

Of this week's top 5 clinical readouts, Johnson & Johnson has the clearest path to approval, since Caplyta now has two positive Phase 3 trials and existing approvals in related indications. Beam follows closely with a pivotal win and a filing planned by year-end, although full response data are still pending. enGene has a filing plan but durability questions, Veradermics has clean data but a pricing hurdle, and PepGen has striking early data but a clinical hold and years of development ahead. The American Society of Hematology meeting in December is the next major catalyst, and all five names are US-listed securities that Canadian investors can reach through their brokerages.